TTE vs RCT Comparisons
Studies that directly compared Target Trial Emulation results with their corresponding Randomized Controlled Trials. Explore 28 comparative studies examining concordance patterns.
Petito (2020)
Disease: Colorectal and pancreatic cancer (Oncology)
Data: Other from US
Sample Size: 6335
(Treatment: 185, Control: 6150)
TTE vs RCT Comparisons
| Target Trial | Outcome | Effect Measure | RCT Result | TTE Result | Concordance |
|---|---|---|---|---|---|
| QUASAR | Overall survival Efficacy | HR |
1.02
[0.70, 1.48] |
1.01
[0.97, 1.05] |
CI Overlap
Same Direction |
| NCIC CTG PA.3 | Overall survival Efficacy | HR |
0.96
[0.74, 1.24] |
1.03
[0.96, 1.09] |
CI Overlap
Different Direction |
Szummer (2020)
Disease: Acture coronary syndrome (Cardiology)
Data: Registry from Sweden
Sample Size: 14091
(Treatment: 8421, Control: 5670)
TTE vs RCT Comparisons
| Target Trial | Outcome | Effect Measure | RCT Result | TTE Result | Concordance |
|---|---|---|---|---|---|
| PLATO | CV Death, MI, Stroke Efficacy | HR |
0.89
[0.74, 1.08] |
0.97
[0.88, 1.06] |
CI Overlap
Same Direction |
| PLATO | Myocardial infarction Efficacy | HR |
0.96
[0.74, 1.25] |
0.80
[0.70, 0.92] |
CI Overlap
Same Direction |
| PLATO | (readmission for) major bleeding Efficacy | HR |
1.02
[0.82, 1.27] |
1.48
[1.25, 1.76] |
CI Overlap
Same Direction |
| PLATO | Stroke Efficacy | HR |
1.58
[0.93, 2.70] |
0.72
[0.56, 0.93] |
CI Overlap
Different Direction |
Admon (2019)
Disease: Hypoxemia (Intensive care)
Data: Rcts from US
Sample Size: 360
(Treatment: 180, Control: 180)
TTE vs RCT Comparisons
| Target Trial | Outcome | Effect Measure | RCT Result | TTE Result | Concordance |
|---|---|---|---|---|---|
| PreVent | Cardiac arrest 1 h after intubation Efficacy | RR |
2.00
[0.40, 10.80] |
0.76
[0.20, 3.40] |
CI Overlap
Different Direction |
| PreVent | Decrease in oxygen saturation % Efficacy | MD |
-1.90
[-4.50, 0.80] |
-4.50
[-6.80, -2.20] |
CI Overlap
Same Direction |
| PreVent | Died before hospital discharge Efficacy | RR |
1.00
[0.80, 1.30] |
1.00
[0.80, 1.30] |
CI Overlap
Same Direction |
| PreVent | ICU-free days Efficacy | MD |
0.10
[-2.20, 2.40] |
0.80
[-1.30, 2.90] |
CI Overlap
Same Direction |
| PreVent | lowest oxygen saturation % Efficacy | MD |
3.90
[1.40, 6.40] |
1.80
[-1.00, 4.60] |
CI Overlap
Same Direction |
| PreVent | lowest oxygen saturation <70% Efficacy | RR |
0.63
[0.30, 1.30] |
0.41
[0.20, 0.90] |
CI Overlap
Same Direction |
| PreVent | lowest oxygen saturation <80% Efficacy | RR |
0.48
[0.30, 0.77] |
0.60
[0.38, 0.93] |
CI Overlap
Same Direction |
| PreVent | lowest oxygen saturation <90% Efficacy | RR |
0.74
[0.60, 1.00] |
0.89
[0.70, 1.20] |
CI Overlap
Same Direction |
| PreVent | Operator-reported aspiration Efficacy | RR |
3.00
[0.40, 10.80] |
0.64
[0.20, 1.90] |
CI Overlap
Different Direction |
| PreVent | Ventilator-free days Efficacy | MD |
-0.50
[-3.00, 1.90] |
0.60
[-1.70, 2.90] |
CI Overlap
Different Direction |
About TTE vs RCT Comparisons
This page showcases studies that directly compared Target Trial Emulation (TTE) results with their corresponding Randomized Controlled Trials (RCTs). These comparisons are crucial for understanding the validity and reliability of the TTE methodology.
Key Metrics:
- CI Overlap: Whether confidence intervals of TTE and RCT estimates overlap
- Direction Agreement: Whether TTE and RCT point to the same conclusion (benefit/harm)
- Effect Measure: The statistical measure used (HR, OR, RR, etc.)
- Transparency: Availability of protocol, data, and analysis code